BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 75,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $33.57, for a total transaction of $2,517,750.00. Following the sale, the chief executive officer now owns 5,023,447 shares in the company, valued at $168,637,115.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neil Kumar also recently made the following trade(s):

• On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total transaction of $1,139,964.02.
• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28.

BridgeBio Pharma Stock Down 5.4 %

NASDAQ:BBIO traded down $1.89 during trading hours on Monday, hitting $33.01. 3,282,866 shares of the stock were exchanged, compared to its average volume of 3,176,007. The company's 50 day moving average is $32.79 and its two-hundred day moving average is $28.40. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47. The company has a market capitalization of $6.28 billion, a P/E ratio of -11.58 and a beta of 1.07.

Remove Ads

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The business had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. On average, equities research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Wall Street Analysts Forecast Growth

BBIO has been the topic of several recent research reports. HC Wainwright restated a "buy" rating and set a $49.00 target price on shares of BridgeBio Pharma in a report on Thursday, February 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a research report on Friday, February 21st. Evercore ISI boosted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday, December 23rd. Citigroup boosted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Bank of America boosted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.67.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Jefferies Financial Group Inc. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $5,076,000. Mackenzie Financial Corp lifted its stake in shares of BridgeBio Pharma by 6.6% in the 4th quarter. Mackenzie Financial Corp now owns 9,505 shares of the company's stock valued at $261,000 after purchasing an additional 592 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $109,000. Frazier Life Sciences Management L.P. lifted its stake in shares of BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company's stock valued at $104,285,000 after purchasing an additional 40,000 shares during the period. Finally, Woodline Partners LP lifted its stake in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company's stock valued at $60,684,000 after purchasing an additional 1,261,772 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.